Susumu Ohwada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susumu Ohwada has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Yasuo Morishita
27 shared publicationsIzumi Takeyoshi
10 shared publicationsSusumu Kawate
Flash hospital
10 shared publicationsYoshihiro Sato
Department of Surgery Gunma University, Graduate School of Medicine 3‐39‐15 Showa‐Machi 371‐8511 Maebashi Japan
10 shared publications- Izumi Takeyoshi
Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine
7 shared publications - Yutaka Sunose
Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine
7 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0574
Gastric Glomus Tumor Mimicking a Neuroendocrine Tumor: A Case Report Highlighting Diagnostic Pitfalls
INTRODUCTION: Gastric glomus tumors (GGTs) are rare mesenchymal neoplasms arising from the modified smooth muscle cells of the glomus body. Their subepithelial location and pronounced hypervascularity overlap considerably with gastrointestinal stromal tumors (GISTs) and neuroendocrine tumors (NETs) on imaging and in small biopsy specimens, making an accurate preoperative diagnosis challenging; as a result, such lesions are frequently diagnosed after surgical resection.CASE PRESENTATION: A 38-year-old asymptomatic woman was found to have a 25-mm well-circumscribed, hypervascular submucosal lesion with a small central depression and minute ulceration in the upper gastric body during a routine health-screening esophagogastroduodenoscopy (EGD). Endoscopic ultrasonography (EUS) demonstrated a heterogeneous hypoechoic mass arising from the third sonographic layer without evidence of muscularis propria invasion. Contrast-enhanced CT showed a hypervascular lesion with no regional lymphadenopathy or distant metastasis. Conventional forceps biopsies targeting the minute ulceration, evaluated with hematoxylin and eosin (H&E) staining alone, were interpreted as consistent with a NET, leading to a provisional diagnosis of a type III gastric NET. Because of the diagnostic uncertainty surrounding the NET diagnosis, and because the EUS and CT showed no evidence of deep or nodal spread, the patient underwent laparoscopic and endoscopic cooperative surgery (LECS) with a local full-thickness gastric resection rather than upfront gastrectomy with lymphadenectomy, and the defect was repaired through a protective mini-laparotomy. Definitive histopathology demonstrated uniform round-to-spindle cells arranged in a perivascular sheet pattern within a myxoid stroma. Immunohistochemistry (IHC) showed focal positivity for α-smooth muscle actin (α-SMA) and negativity for KIT (CD117), CD34, chromogranin A, synaptophysin, desmin, and the S-100 protein, confirming a GGT. All surgical margins were negative, and no recurrence has been observed over 5 years of follow-up.CONCLUSIONS: A GGT must be included in the differential diagnosis of hypervascular gastric subepithelial lesions (SELs), including those with a nested, NET-like architecture. H&E staining alone is insufficient for a definitive diagnosis; direct communication with the pathologist and comprehensive IHC profiling are indispensable. LECS is a favorable and effective organ-preserving strategy for localized gastric SELs when the diagnosis remains uncertain despite the preoperative evaluation.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0574
Open AccessGastric Glomus Tumor Mimicking a Neuroendocrine Tumor: A Case Report Highlighting Diagnostic Pitfalls
INTRODUCTION: Gastric glomus tumors (GGTs) are rare mesenchymal neoplasms arising from the modified smooth muscle cells of the glomus body. Their subepithelial location and pronounced hypervascularity overlap considerably with gastrointestinal stromal tumors (GISTs) and neuroendocrine tumors (NETs) on imaging and in small biopsy specimens, making an accurate preoperative diagnosis challenging; as a result, such lesions are frequently diagnosed after surgical resection.CASE PRESENTATION: A 38-year-old asymptomatic woman was found to have a 25-mm well-circumscribed, hypervascular submucosal lesion with a small central depression and minute ulceration in the upper gastric body during a routine health-screening esophagogastroduodenoscopy (EGD). Endoscopic ultrasonography (EUS) demonstrated a heterogeneous hypoechoic mass arising from the third sonographic layer without evidence of muscularis propria invasion. Contrast-enhanced CT showed a hypervascular lesion with no regional lymphadenopathy or distant metastasis. Conventional forceps biopsies targeting the minute ulceration, evaluated with hematoxylin and eosin (H&E) staining alone, were interpreted as consistent with a NET, leading to a provisional diagnosis of a type III gastric NET. Because of the diagnostic uncertainty surrounding the NET diagnosis, and because the EUS and CT showed no evidence of deep or nodal spread, the patient underwent laparoscopic and endoscopic cooperative surgery (LECS) with a local full-thickness gastric resection rather than upfront gastrectomy with lymphadenectomy, and the defect was repaired through a protective mini-laparotomy. Definitive histopathology demonstrated uniform round-to-spindle cells arranged in a perivascular sheet pattern within a myxoid stroma. Immunohistochemistry (IHC) showed focal positivity for α-smooth muscle actin (α-SMA) and negativity for KIT (CD117), CD34, chromogranin A, synaptophysin, desmin, and the S-100 protein, confirming a GGT. All surgical margins were negative, and no recurrence has been observed over 5 years of follow-up.CONCLUSIONS: A GGT must be included in the differential diagnosis of hypervascular gastric subepithelial lesions (SELs), including those with a nested, NET-like architecture. H&E staining alone is insufficient for a definitive diagnosis; direct communication with the pathologist and comprehensive IHC profiling are indispensable. LECS is a favorable and effective organ-preserving strategy for localized gastric SELs when the diagnosis remains uncertain despite the preoperative evaluation.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0350
Life-Threatening Melena from Deep Ileal Angiodysplasia Successfully Treated by Intraoperative Enteroscopy–Guided Segmental Resection: A Case Report
INTRODUCTION: Small bowel angiodysplasia (AGD) is a common yet diagnostically challenging cause of gastrointestinal (GI) bleeding in older patients, particularly in those receiving anticoagulants. In hemodynamically unstable cases where conventional modalities fail, intraoperative enteroscopy (IOE) remains an important rescue modality.CASE PRESENTATION: An 85-year-old man receiving apixaban presented with life-threatening melena and hemorrhagic shock (hemoglobin nadir 5.5 g/dL). Esophagogastroduodenoscopy, colonoscopy, and selective mesenteric angiography were all non-diagnostic. Dynamic contrast-enhanced CTA demonstrated active contrast extravasation in the deep ileum. An emergency laparotomy with IOE was performed: a sterile upper GI endoscope was introduced through a mid-intestinal enterotomy and advanced bi-directionally; systematic intraluminal irrigation with warmed saline via a water-jet system restored clear visualization of the small bowel mucosa; and a minute, actively spurting vascular lesion was identified in the deep ileum. A targeted 10-cm segmental resection with primary anastomosis was performed. No gross abnormalities were evident in the resected specimen; however, histopathology confirmed AGD with dilated, tortuous submucosal vessels. No recurrent bleeding was observed over 1 year of follow-up.CONCLUSIONS: IOE-guided surgery is a definitive diagnostic and therapeutic option in life-threatening small bowel bleeding when standard modalities fail. Early multidisciplinary decision-making and prompt surgical intervention are essential in such high-risk older patients receiving anticoagulation therapy.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0350
Open AccessLife-Threatening Melena from Deep Ileal Angiodysplasia Successfully Treated by Intraoperative Enteroscopy–Guided Segmental Resection: A Case Report
INTRODUCTION: Small bowel angiodysplasia (AGD) is a common yet diagnostically challenging cause of gastrointestinal (GI) bleeding in older patients, particularly in those receiving anticoagulants. In hemodynamically unstable cases where conventional modalities fail, intraoperative enteroscopy (IOE) remains an important rescue modality.CASE PRESENTATION: An 85-year-old man receiving apixaban presented with life-threatening melena and hemorrhagic shock (hemoglobin nadir 5.5 g/dL). Esophagogastroduodenoscopy, colonoscopy, and selective mesenteric angiography were all non-diagnostic. Dynamic contrast-enhanced CTA demonstrated active contrast extravasation in the deep ileum. An emergency laparotomy with IOE was performed: a sterile upper GI endoscope was introduced through a mid-intestinal enterotomy and advanced bi-directionally; systematic intraluminal irrigation with warmed saline via a water-jet system restored clear visualization of the small bowel mucosa; and a minute, actively spurting vascular lesion was identified in the deep ileum. A targeted 10-cm segmental resection with primary anastomosis was performed. No gross abnormalities were evident in the resected specimen; however, histopathology confirmed AGD with dilated, tortuous submucosal vessels. No recurrent bleeding was observed over 1 year of follow-up.CONCLUSIONS: IOE-guided surgery is a definitive diagnostic and therapeutic option in life-threatening small bowel bleeding when standard modalities fail. Early multidisciplinary decision-making and prompt surgical intervention are essential in such high-risk older patients receiving anticoagulation therapy.
- 15 September 2023
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 367 (1) , e8-e9
Scabies tunnel and lesions
- 15 September 2023
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 367 (1) , e8-e9
Scabies tunnel and lesions
- Open Access
- 2 February 2023
- Published by Springer Nature in Research Square
A novel pancreaticoduodenectomy reconstruction for a patient with Roux-en-Y hepaticojejunostomy after radical extended left hepatectomy for perihilar cholangiocarcinoma
Background: Metachronous cholangiocarcinoma in the remnant distal bile duct (BD) has been reported after the resection of perihilar cholangiocarcinoma. A pancreatoduodenectomy (PD) after radically extended hepatectomy with Roux-en-Y hepaticojejunostomy has significant surgical complexity in in both extensive adhesiolysis and digestive tract reconstruction. Herein, we reported a novel method of digestive tract reconstruction using the Y limb of pre-existing Roux-en-Y hepaticojejunostomy for pancreaticoduodenostomy and, subsequently, the Roux jejunal limb for gastrojejunostomy. Case presentation: A 74-year-old male developed distal BD cholangiocarcinoma six months after extended left hepatectomy for perihilar cholangiocarcinoma and subsequent adjuvant chemotherapy. The patient underwent extensive adhesiolysis followed by PD. His digestive tract was reconstructed by a novel method of PD reconstruction: the Y limb of the pre-existing Roux-en-Y hepaticojejunostomy was used for pancreaticoduodenostomy, and the Roux jejunal limb was used for the gastrojejunostomy. The tumor pathology demonstrated histologically stage Ib biliary duct adenocarcinoma with fibromuscular invasion.There were no complications of a pancreaticodeodenostomy fistula. Conclusions: This novel method of PD reconstruction for patients with Roux-en-Y hepaticojejunostomy could take advantage of the previous surgically altered anatomy and avoid further adhesiolysis for obtaining the adequate length of a new jejunal loop for pancreaticojejunostomy and gastrojejunostomy. This can be an optional PD reconstruction for patients with Roux-en-Y hepaticojejunostomy in cases of early-stage bile duct cancer and/or less likely to have lymph node metastasis.
- 2 February 2023
- Published by Springer Nature in Research Square
Open AccessA novel pancreaticoduodenectomy reconstruction for a patient with Roux-en-Y hepaticojejunostomy after radical extended left hepatectomy for perihilar cholangiocarcinoma
Background: Metachronous cholangiocarcinoma in the remnant distal bile duct (BD) has been reported after the resection of perihilar cholangiocarcinoma. A pancreatoduodenectomy (PD) after radically extended hepatectomy with Roux-en-Y hepaticojejunostomy has significant surgical complexity in in both extensive adhesiolysis and digestive tract reconstruction. Herein, we reported a novel method of digestive tract reconstruction using the Y limb of pre-existing Roux-en-Y hepaticojejunostomy for pancreaticoduodenostomy and, subsequently, the Roux jejunal limb for gastrojejunostomy. Case presentation: A 74-year-old male developed distal BD cholangiocarcinoma six months after extended left hepatectomy for perihilar cholangiocarcinoma and subsequent adjuvant chemotherapy. The patient underwent extensive adhesiolysis followed by PD. His digestive tract was reconstructed by a novel method of PD reconstruction: the Y limb of the pre-existing Roux-en-Y hepaticojejunostomy was used for pancreaticoduodenostomy, and the Roux jejunal limb was used for the gastrojejunostomy. The tumor pathology demonstrated histologically stage Ib biliary duct adenocarcinoma with fibromuscular invasion.There were no complications of a pancreaticodeodenostomy fistula. Conclusions: This novel method of PD reconstruction for patients with Roux-en-Y hepaticojejunostomy could take advantage of the previous surgically altered anatomy and avoid further adhesiolysis for obtaining the adequate length of a new jejunal loop for pancreaticojejunostomy and gastrojejunostomy. This can be an optional PD reconstruction for patients with Roux-en-Y hepaticojejunostomy in cases of early-stage bile duct cancer and/or less likely to have lymph node metastasis.
- Open Access
- 25 March 2021
- Published by Springer Nature in Surgical Case Reports
- Vol. 7 (1) , 1-6
A case of 18 years disease-free survival after combined pancreatoduodenectomy and hemicolectomy for carcinosarcoma of the transverse colon
Background: Ascertaining the origin of large tumors located in the region of the pancreas head and adjacent mesocolon can pose a challenge preoperatively. En bloc pancreatoduodenectomy with hemicolectomy is often required towards curative tumor resection (R0) of malignant tumors in this region. Case presentation: Herein we report a case of a 48-year-old man with two contiguous masses each 5 cm in size, located in the pancreatic head. The masses were detected incidentally by abdominal ultrasonography at an annual health check. Endoscopic biopsies revealed inflammation with no malignancy. Cross-sectional imaging showed the tumor direct invasion of the uncinate process of the pancreas, and the third portion of the duodenum. Based on imaging, a malignant submucosal tumor originating from mesenchymal cells in the mesentery of the transverse colon was made preoperatively. The mass required en bloc pancreatoduodenectomy, right hemicolectomy, and resection of the superior mesenteric vein. The final pathology was carcinosarcoma of the transverse colon. The patient survived 18 years after surgery without recurrence. Conclusions: Malignant tumors located in the region of the pancreas head should be considered for an en bloc curative tumor resection and adjuvant chemotherapy treatments offered that might be beneficial for carcinosarcoma.
- 25 March 2021
- Published by Springer Nature in Surgical Case Reports
- Vol. 7 (1) , 1-6
Open AccessA case of 18 years disease-free survival after combined pancreatoduodenectomy and hemicolectomy for carcinosarcoma of the transverse colon
Background: Ascertaining the origin of large tumors located in the region of the pancreas head and adjacent mesocolon can pose a challenge preoperatively. En bloc pancreatoduodenectomy with hemicolectomy is often required towards curative tumor resection (R0) of malignant tumors in this region. Case presentation: Herein we report a case of a 48-year-old man with two contiguous masses each 5 cm in size, located in the pancreatic head. The masses were detected incidentally by abdominal ultrasonography at an annual health check. Endoscopic biopsies revealed inflammation with no malignancy. Cross-sectional imaging showed the tumor direct invasion of the uncinate process of the pancreas, and the third portion of the duodenum. Based on imaging, a malignant submucosal tumor originating from mesenchymal cells in the mesentery of the transverse colon was made preoperatively. The mass required en bloc pancreatoduodenectomy, right hemicolectomy, and resection of the superior mesenteric vein. The final pathology was carcinosarcoma of the transverse colon. The patient survived 18 years after surgery without recurrence. Conclusions: Malignant tumors located in the region of the pancreas head should be considered for an en bloc curative tumor resection and adjuvant chemotherapy treatments offered that might be beneficial for carcinosarcoma.
- 1 November 2008
- Vol. 35 (11) , 1915-7
[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
Gemcitabine(GEM)is the standard therapy for advanced pancreatic cancer. GEM-oxaliplatin (GEMOX) combination treatment has been reported to be superior to GEM alone in terms of clinical progression-free survival, but it is not the therapy of choice for pancreatic cancer. We report a case of advanced mucinous cystic neoplasm (MCN) of the pancreas with multiple hepatic metastases in a 39-year-old female. She was treated with 16 courses of GEMOX (GEM 1,500 mg/day at a rate of 10 mg/m2/min on the first day and oxaliplatin 150 mg/day at 100 mg/m2 on the second day, every 3 weeks). The pharmacist helped her to avoid severe side effects. When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment. No recurrence has been observed 22 months postoperatively. GEMOX might be effective for the treatment of MCN of the pancreas.
- 1 November 2008
- Vol. 35 (11) , 1915-7
[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
Gemcitabine(GEM)is the standard therapy for advanced pancreatic cancer. GEM-oxaliplatin (GEMOX) combination treatment has been reported to be superior to GEM alone in terms of clinical progression-free survival, but it is not the therapy of choice for pancreatic cancer. We report a case of advanced mucinous cystic neoplasm (MCN) of the pancreas with multiple hepatic metastases in a 39-year-old female. She was treated with 16 courses of GEMOX (GEM 1,500 mg/day at a rate of 10 mg/m2/min on the first day and oxaliplatin 150 mg/day at 100 mg/m2 on the second day, every 3 weeks). The pharmacist helped her to avoid severe side effects. When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment. No recurrence has been observed 22 months postoperatively. GEMOX might be effective for the treatment of MCN of the pancreas.
- Open Access
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (31) , 4880-4888
Prognostic significance of BMP and activin membranebound inhibitor in colorectal cancer
Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (31) , 4880-4888
Open AccessPrognostic significance of BMP and activin membranebound inhibitor in colorectal cancer
Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer
- 24 April 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (6) , 1217-1222
Left Renal Vein Graft for Vascular Reconstruction in Abdominal Malignancy
Background Advanced abdominal malignancies are occasionally invasive for the major blood vessels, such as the portal vein (PV), inferior vena cava (IVC), and major hepatic veins (HVs), and complete removal of the tumors is required for patients undergoing vascular resection and reconstruction. We used left renal vein (LRV) grafts for vascular reconstruction in patients with these malignancies and evaluated their clinical relevance. Methods A total of 113 patients underwent vascular resection including the PV (42 patients), IVC (68 patients), and HV (3 patients) for hepatobiliary-pancreatic or abdominal tumor resection. Of these, 11 patients underwent vascular reconstruction with a LRV graft of the PV, superior mesenteric vein (SMV), and HVs in 3 patients each, and the IVC in 2 patients. The HVs were resected with segmentectomy involving Couinaud’s segments VII, VIII, and IV; VII, VIII, and II; or III, IV, VIII in each patient. The PV and SMV were resected in 5 patients undergoing pancreaticoduodenectomy for pancreatic carcinoma, and in 1 patient being treated with extended right hepatectomy and pancreaticoduodenectomy for hepatic hilar carcinoma. The IVC was partially resected in 1 patient with advanced colon cancer and 1 with malignant schwannoma. Results The mean graft length of LRV obtained was 3.6 (3.5–4.0) cm. The graft was used as a tube in 9 patients, and as a patch in 2 patients. The mean duration of clamping time was 41.9 (35–60) min. Portal vein thrombosis was encountered in 2 patients, and anastomotic stenosis in 1 patient. Other morbidity was not related to vascular reconstruction. One patient who underwent extended right hepatectomy and pancreaticoduodenectomy died of liver failure in the hospital. The serum creatinine level after surgery did not deteriorate except in the one patient who died in the hospital. Graft patency was maintained during the follow-up period in all patients. Conclusions A LRV graft may enhance the possibility of vascular reconstruction without deteriorating serum creatinine level, and it provides sound graft patency.
- 24 April 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (6) , 1217-1222
Left Renal Vein Graft for Vascular Reconstruction in Abdominal Malignancy
Background Advanced abdominal malignancies are occasionally invasive for the major blood vessels, such as the portal vein (PV), inferior vena cava (IVC), and major hepatic veins (HVs), and complete removal of the tumors is required for patients undergoing vascular resection and reconstruction. We used left renal vein (LRV) grafts for vascular reconstruction in patients with these malignancies and evaluated their clinical relevance. Methods A total of 113 patients underwent vascular resection including the PV (42 patients), IVC (68 patients), and HV (3 patients) for hepatobiliary-pancreatic or abdominal tumor resection. Of these, 11 patients underwent vascular reconstruction with a LRV graft of the PV, superior mesenteric vein (SMV), and HVs in 3 patients each, and the IVC in 2 patients. The HVs were resected with segmentectomy involving Couinaud’s segments VII, VIII, and IV; VII, VIII, and II; or III, IV, VIII in each patient. The PV and SMV were resected in 5 patients undergoing pancreaticoduodenectomy for pancreatic carcinoma, and in 1 patient being treated with extended right hepatectomy and pancreaticoduodenectomy for hepatic hilar carcinoma. The IVC was partially resected in 1 patient with advanced colon cancer and 1 with malignant schwannoma. Results The mean graft length of LRV obtained was 3.6 (3.5–4.0) cm. The graft was used as a tube in 9 patients, and as a patch in 2 patients. The mean duration of clamping time was 41.9 (35–60) min. Portal vein thrombosis was encountered in 2 patients, and anastomotic stenosis in 1 patient. Other morbidity was not related to vascular reconstruction. One patient who underwent extended right hepatectomy and pancreaticoduodenectomy died of liver failure in the hospital. The serum creatinine level after surgery did not deteriorate except in the one patient who died in the hospital. Graft patency was maintained during the follow-up period in all patients. Conclusions A LRV graft may enhance the possibility of vascular reconstruction without deteriorating serum creatinine level, and it provides sound graft patency.
- 1 December 2006
- Vol. 33 (13) , 2073-6
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
We report a recurrent case of gastric endocrine cell cancer that showed a remarkable response to systemic chemotherapy. A 70-year-old male who underwent gastroscopy at our hospital showed a 0-IIa-like lesion, but no abnormal CT findings. He was diagnosed with gastric cancer, and underwent a proximal gastrectomy. The resected specimen showed endocrine cell cancer. The tumor was Grimelius-positive histologically and chromogranin A-and NSE-positive immunohistochemically. About 2 years after surgery, liver, lymph node, and bone metastases were detected. Systemic chemotherapy with TS-1 and CDDP was started, and the lesions progressed. Then, by approximately 1 year after CDDP and CPT-11 treatments, the recurrent lesions had diminished remarkably and were no longer seen on CT or FDG-PET.
- 1 December 2006
- Vol. 33 (13) , 2073-6
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
We report a recurrent case of gastric endocrine cell cancer that showed a remarkable response to systemic chemotherapy. A 70-year-old male who underwent gastroscopy at our hospital showed a 0-IIa-like lesion, but no abnormal CT findings. He was diagnosed with gastric cancer, and underwent a proximal gastrectomy. The resected specimen showed endocrine cell cancer. The tumor was Grimelius-positive histologically and chromogranin A-and NSE-positive immunohistochemically. About 2 years after surgery, liver, lymph node, and bone metastases were detected. Systemic chemotherapy with TS-1 and CDDP was started, and the lesions progressed. Then, by approximately 1 year after CDDP and CPT-11 treatments, the recurrent lesions had diminished remarkably and were no longer seen on CT or FDG-PET.
- Open Access
- 1 January 2006
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 67 (6) , 1433-1437
RETROPERITONEAL MYELOLIPOMA-A CASE REPORT-
- 1 January 2006
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 67 (6) , 1433-1437
Open AccessRETROPERITONEAL MYELOLIPOMA-A CASE REPORT-